Literature DB >> 30979708

An alternatively transcribed TAZ variant negatively regulates JAK-STAT signaling.

Chuantao Fang1, Jian Li1, Sixian Qi1, Yubin Lei1, Yan Zeng1, Pengcheng Yu2,3, Zhaolan Hu4, Yufeng Zhou1, Yulong Wang2,3, Ruping Dai4, Jin Li1, Shenglin Huang5, Pinglong Xu6, Kang Chen7,8,9, Chen Ding10, Fa-Xing Yu11.   

Abstract

Type I interferon (IFN)-induced Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling drives the expression of IFN-stimulated genes (ISGs) to mediate antiviral response. The strength and duration of JAK-STAT signaling are tightly regulated to ensure effective antiviral defense while avoiding pathological inflammation and autoimmunity. Here, we report that cTAZ, an isoform of the Hippo pathway effector TAZ, is transcribed by an alternative promoter. Although majority of C-terminal sequences of TAZ is retained, cTAZ is not regulated by the Hippo signaling and does not mediate its growth-inhibitory functions. Instead, cTAZ negatively regulates JAK-STAT signaling by inhibiting STAT1/2 nuclear localization and ISG expression, and its expression is induced by type I IFN Thus, cTAZ functions as a modulator of JAK-STAT signaling and may play a role in fine-tuning cellular antiviral response.
© 2019 The Authors.

Entities:  

Keywords:  Hippo pathway; JAK‐STAT pathway; alternative transcript; viral infection

Mesh:

Substances:

Year:  2019        PMID: 30979708      PMCID: PMC6549033          DOI: 10.15252/embr.201847227

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  46 in total

1.  Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA.

Authors:  X Chen; U Vinkemeier; Y Zhao; D Jeruzalmi; J E Darnell; J Kuriyan
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

2.  Role of YAP/TAZ in mechanotransduction.

Authors:  Sirio Dupont; Leonardo Morsut; Mariaceleste Aragona; Elena Enzo; Stefano Giulitti; Michelangelo Cordenonsi; Francesca Zanconato; Jimmy Le Digabel; Mattia Forcato; Silvio Bicciato; Nicola Elvassore; Stefano Piccolo
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

Review 3.  Immunomodulatory functions of type I interferons.

Authors:  José M González-Navajas; Jongdae Lee; Michael David; Eyal Raz
Journal:  Nat Rev Immunol       Date:  2012-01-06       Impact factor: 53.106

4.  TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition.

Authors:  Heng Zhang; Chen-Ying Liu; Zheng-Yu Zha; Bin Zhao; Jun Yao; Shimin Zhao; Yue Xiong; Qun-Ying Lei; Kun-Liang Guan
Journal:  J Biol Chem       Date:  2009-03-26       Impact factor: 5.157

5.  STAT2 deficiency and susceptibility to viral illness in humans.

Authors:  Sophie Hambleton; Stephen Goodbourn; Dan F Young; Paul Dickinson; Siti M B Mohamad; Manoj Valappil; Naomi McGovern; Andrew J Cant; Scott J Hackett; Peter Ghazal; Neil V Morgan; Richard E Randall
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-07       Impact factor: 11.205

6.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control.

Authors:  Bin Zhao; Xiaomu Wei; Weiquan Li; Ryan S Udan; Qian Yang; Joungmok Kim; Joe Xie; Tsuneo Ikenoue; Jindan Yu; Li Li; Pan Zheng; Keqiang Ye; Arul Chinnaiyan; Georg Halder; Zhi-Chun Lai; Kun-Liang Guan
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

Review 7.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer.

Authors:  Fa-Xing Yu; Bin Zhao; Kun-Liang Guan
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

Review 8.  Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.

Authors:  Serge Y Fuchs
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

9.  A diverse range of gene products are effectors of the type I interferon antiviral response.

Authors:  John W Schoggins; Sam J Wilson; Maryline Panis; Mary Y Murphy; Christopher T Jones; Paul Bieniasz; Charles M Rice
Journal:  Nature       Date:  2011-04-10       Impact factor: 49.962

10.  Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade.

Authors:  Qian Zhang; Fansen Meng; Shasha Chen; Steven W Plouffe; Shiying Wu; Shengduo Liu; Xinran Li; Ruyuan Zhou; Junxian Wang; Bin Zhao; Jianming Liu; Jun Qin; Jian Zou; Xin-Hua Feng; Kun-Liang Guan; Pinglong Xu
Journal:  Nat Cell Biol       Date:  2017-03-27       Impact factor: 28.824

View more
  4 in total

1.  YAP/TAZ deficiency reprograms macrophage phenotype and improves infarct healing and cardiac function after myocardial infarction.

Authors:  Masum M Mia; Dasan Mary Cibi; Siti Aishah Binte Abdul Ghani; Weihua Song; Nicole Tee; Sujoy Ghosh; Junhao Mao; Eric N Olson; Manvendra K Singh
Journal:  PLoS Biol       Date:  2020-12-02       Impact factor: 8.029

Review 2.  The Crosstalk Between Hippo-YAP Pathway and Innate Immunity.

Authors:  Shuai Wang; Lili Zhou; Li Ling; Xuli Meng; Feng Chu; Suping Zhang; Fangfang Zhou
Journal:  Front Immunol       Date:  2020-02-27       Impact factor: 7.561

Review 3.  The Hippo Pathway in Innate Anti-microbial Immunity and Anti-tumor Immunity.

Authors:  Qian Zhang; Ruyuan Zhou; Pinglong Xu
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

Review 4.  The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer.

Authors:  Richard Cunningham; Carsten Gram Hansen
Journal:  Clin Sci (Lond)       Date:  2022-02-11       Impact factor: 6.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.